18F-FECNT: Validation as PET dopamine transporter ligand in parkinsonism

Experimental Neurology

Volumn 226, Issue 2, 2010, Pages 265-273

  Masilamoni, Gunasingh ^a   Votaw, John ^b   Howell, Leonard ^a   Villalba, Rosa M ^a   Goodman, Mark ^b   Voll, Ronald J ^a   Stehouwer, Jeffrey ^a   Wichmann, Thomas ^a,b   Smith, Yoland ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Brain imaging; Dopamine; Midbrain; Monkey; MPTP; Parkinson's disease; Primate; Striatum; Substantianigra; Transporter

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2BETA CARBOMETHOXY 3BETA (4 CHLOROPHENYL) 8 (2 FLUOROETHYL)NORTROPANE F 18; DOPAMINE TRANSPORTER; TRACER; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL LOSS; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINERGIC NERVE CELL; FEMALE; IMMUNOREACTIVITY; MESENCEPHALON; MONKEY; NONHUMAN; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; AUTORADIOGRAPHY; BEHAVIORAL SYMPTOMS; BRAIN; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FLUORINE RADIOISOTOPES; LIGANDS; MACACA MULATTA; MPTP POISONING; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

EID: 77958492669     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.08.024     Document Type: Article

References (39)

1. Alvarez-Fischer D., Blessmann G., Trosowski C., Béhé M., Schurrat T., Hartmann A., Behr T.M., Oertel W.H., Höglinger G.U., Höffken H. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. Neuroimage 2007, 38:5-12.
2. Amara S.G., Sonders M.S. Neurotransmitter transporters as molecular targets for addictive drugs. Drug Alcohol Depend. 1998, 51:87-96.
3. Ashkan K., Wallace B.A., Mitrofanis J., Pollo C., Brard P.Y., Fagret D., Benabid A.L. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease. Parkinsonism Relat. Disord. 2007, 13:266-275.
4. Badgaiyan R.D., Fischman A.J., Alpert N.M. Dopamine release during human emotional processing. Neuroimage 2009, 47:2041-2045.
5. Bernheimer H., Birkmayer W., Hornykiewicz O., Jellinger K., Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J. Neurol. Sci. 1973, 20:415-455.
6. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., Niznik H.B., Levey A.I. The dopamine transporter: immunochemical characterization and localization in brain. J. Neurosci. 1995, 15:1714-1723.
7. Costa A., Peppe A., Dell'Agnello G., Caltagirone C., Carlesimo G.A. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory. Neuropsychologia 2009, 47:1374-1381.
8. Davis M.R., Votaw J.R., Bremner J.D., Byas-Smith M.G., Faber T.L., Voll R.J., Hoffman J.M., Grafton S.T., Kilts C.D., Goodman M.M. Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J. Nucl. Med. 2003, 44:855-861.
9. Dorsey E.R., Holloway R.G., Ravina B.M. Status of biological markers. Parkinson's Disease - Diagnosis and Clinical Management 2008, 277-284. Demos, New York. S.A. Factor, W.J. Weiner (Eds.).
10. Giros B., Caron M.G. Molecular characterization of the dopamine transporter. Trends Pharmacol. Sci. 1993, 14:43-49.
11. Goodman M.M., Keil R., Shoup T.M., Eshima D., Eshima L., Kilts C., Votaw J., Camp V.M., Votaw D., Smith E., Kung M.P., Malveaux E., Watts R., Huerkamp M., Wu D., Garcia E., Hoffman J.M. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J. Nucl. Med. 1997, 38:119-126.
12. Goodman M.M., Kilts C.D., Keil R., Shi B., Martarello L., Xing D., Votaw J., Ely T.D., Lambert P., Owens M.J., Camp V.M., Malveaux E., Hoffman J.M. 18F-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl. Med. Biol. 2000, 27:1-12.
13. Herkenham M., Little M.D., Bankiewicz K., Yang S.C., Markey S.P., Johannessen J.N. Selective retention of MPP+within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 1991, 40:133-158.
14. Hirvonen J., Johansson J., Teräs M., Oikonen V., Lumme V., Virsu P., Roivainen A., Någren K., Halldin C., Farde L., Hietala J. Measurement of striatal and extrastriatal dopamine transporter binding with high-resolution PET and [11C]PE2I: quantitative modeling and test-retest reproducibility. J. Cereb. Blood Flow Metab. 2008, 28:1059-1069.
15. Hoffman B.J., Hansson S.R., Mezey E., Palkovits M. Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front. Neuroendocrinol. 1998, 19:187-231.
16. Honer M., Hengerer B., Blagoev M., Hintermann S., Waldmeier P., Schubiger P.A., Ametamey S.M. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl. Med. Biol. 2006, 33:607-614.
17. Ito Y., Fujita M., Shimada S., Watanabe Y., Okada T., Kusuoka H., Tohyama M., Nishimura T. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 1999, 31:178-185.
18. Jenner P. The MPTP-treated primate as a model of motor complications in PD: primate model of motor complications. Neurology 2003, 23(61):S4-S11.
19. Kazumata K., Dhawan V., Chaly T., Antonini A., Margouleff C., Belakhlef A., Neumeyer J., Eidelberg D. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J. Nucl. Med. 1998, 39:1521-1530.
20. Kuhar M.J., Sanchez-Roa P.M., Wong D.F., Dannals R.F., Grigoriadis D.E., Lew R., Milberger M. Dopamine transporter: biochemistry, pharmacology and imaging. Eur. Neurol. 1990, 30:15-20.
21. Lee C.S., Samii A., Sossi V., Ruth T.J., Schulzer M., Holden J.E., Wudel J., Pal P.K., dela Fuente-Fernandez R., Calne D.B., Stoessl A.J. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopamine nerve terminals in Parkinson's disease. Ann. Neurol. 2000, 474:493-503.
22. Mach R.H., Nader M.A., Ehrenkaufer R.L., Gage H.D., Childers S.R., Hodges L.M., Hodges M.M., Davies H.M. Fluorine-18-labeled tropane analogs for PET imaging studies of the dopamine transporter. Synapse 2000, 37:109-117.
23. Nagai Y., Obayashi S., Ando K., Inaji M., Maeda J., Okauchi T., Ito H., Suhara T. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007, 61:809-819.
24. Okauchi T., Suhara T., Maeda J., Kawabe K., Obayashi S., Suzuki K. Effect of endogenous dopamine on endogenous dopamine on extrastriated [11C]FLB 457 binding measured by PET. Synapse 2001, 41:87-95.
25. Parent A., Hazrati L.N. Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res. Brain Res. Rev. 1995, 20:91-127.
26. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., Ruth T.J., Calne D.B. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Ann. Neurol. 1993, 34:331-338.
27. Pavese N., Brooks D.J. Imaging neurodegeneration in Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:722-729.
28. Poyot T., Condé F., Grégoire M.C., Frouin V., Coulon C., Fuseau C., Hinnen F., Dollé F., Hantraye P., Bottlaender M. Anatomic and biochemical correlates of the dopamine transporter ligand 11C-PE2I in normal and parkinsonian primates: comparison with 6-[18F]fluoro-L-dopa. J. Cereb. Blood Flow Metab. 2001, 21:782-792.
29. Ribeiro M.J., Vidailhet M., Loch C., Dupel C., Nguyen J.P., Ponchant M., Dolle F., Peschanski M., Hantraye P., Cesaro P., Samson Y., Remy P. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch. Neurol. 2002, 59:580-586.
30. Scheller D., Chan P., Li Q., Wu T., Zhang R., Guan L., Ravenscroft P., Guigoni C., Crossman A.R., Hill M., Bezard E. Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinson's disease. Exp. Neurol. 2007, 203:415-422.
31. Shimada S., Kitayama S., Walther D., Uhl G. Dopamine transporter mRNA: dense expression in ventral midbrain neurons. Brain Res. Mol. Brain Res. 1992, 13:359-362.
32. Smith Y., Bolam J.P. Convergence of synaptic inputs from the striatum and the globus pallidus onto identified nigrocollicular cells in the rat: a double anterograde labelling study. Neuroscience 1991, 44:45-73.
33. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., Kimura H. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Ann. Neurol. 1993, 34:324-330.
34. Stout D., Petric A., Satyamurthy N., Nguyen Q., Huang S.C., Namavari M., Barrio J.R. 2Beta-carbomethoxy-3beta-(4- and 2-[18F]fluoromethylphenyl) tropanes: specific probes for in vivo quantification of central dopamine transporter sites. Nucl. Med. Biol. 1999, 26:897-903.
35. Torres G.E., Gainetdinov R.R., Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 2003, 4:13-25.
36. Votaw J.R., Howell L.L., Martarello L., Hoffman J.M., Kilts C.D., Lindsey K.P., Goodman M.M. Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse 2002, 44:203-210.
37. Wichmann T., DeLong M.R. Pathophysiology of Parkinson's disease: the MPTP primate model of the human disorder. Ann. NY Acad. Sci. 2003, 991:199-213.
38. Yee R.E., Irwin I., Milonas C., Stout D.B., Huang S.C., Shoghi-Jadid K., Satyamurthy N., Delanney L.E., Togasaki D.M., Farahani K.F., Delfani K., Janson A.M., Phelps M.E., Langston J.W., Barrio J.R. Novel observations with FDOPA-PET imaging after early nigrostriatal damage. Mov. Disord. 2001, 16:838-848.
39. Xing D., Chen P., Keil R., Kilts C.D., Shi B., Camp V.M., Malveaux G., Ely T., Owens M.J., Votaw J., Davis M., Hoffman J.M., BaKay R.A., Subramanian T., Watts R.L., Goodman M.M. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2beta-carbo-1'-fluoro-2-propoxy-3beta-(4-chlorophenyl)tr opanes. Ligands for the imaging of dopamine transporters by positron emission tomography. J. Med. Chem. 2000, 43:639-648.